Health & Fitness
Health and Fitness
Health and Fitness
Tue, February 10, 2009
Mon, February 9, 2009
Sucampo to Release Full Year 2008 Financial Results and Conduct a Conference Call on February 19, 2009
BETHESDA, Md.--([ BUSINESS WIRE ])--Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) today announced that it will sponsor a conference call to discuss its financial results for the quarter and year ended December 31, 2008. These results are expected to be disclosed on Thursday, February 19, 2009, after the capital markets close.
The conference call will be hosted by senior management and will be held at 4:30 pm Eastern on February 19, 2009.
Investors may listen to the live call by dialing 866-700-7441 (domestic) or 617-213-8839 (international), passcode 19518394, five to ten minutes ahead of the start of the call. A replay of the call will be available within a few hours after the call ends. Investors may listen to the replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 99595043.
The conference call will be webcast and may be accessed at the "For Investors" section of the company's website, [ www.sucampo.com ]. Investors interested in listening to the live audio webcast should log on before the conference call begins in order to download any software required. The archive of the conference call will remain available for several days.
About Sucampo Pharmaceuticals
Sucampo Pharmaceuticals, Inc., a biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which are bio-lipids that occur naturally in the human body, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development.
Sucampo Pharma America, Inc., markets AMITIZA® (lubiprostone) 24 mcg in the U.S. for chronic idiopathic constipation in adults and AMITIZA 8 mcg in the U.S. to treat irritable bowel syndrome with constipation in adult women. Sucampo also is developing the drug for additional gastrointestinal disorders with large potential markets. In addition, Sucampo has a robust pipeline of compounds with the potential to target underserved diseases affecting millions of patients worldwide. Sucampo Pharmaceuticals, Inc. has three wholly owned subsidiaries: Sucampo Pharma Europe, Ltd., located in the UK; Sucampo Pharma, Ltd., located in Japan; and, Sucampo Pharma Americas, Inc., located in Maryland. To learn more about Sucampo Pharmaceuticals and its products, visit [ www.sucampo.com ].
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Sucampo Pharmaceuticals are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words "project," "believe," "anticipate," "plan," "expect," "estimate," "intend," "should," "would," "could," "will," "may" or other similar expressions. Forward-looking statements include statements about potential trial results, the potential utility of AMITIZA to treat particular indications and expected data availability and regulatory filing dates. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in Sucampo Pharmaceuticals' filings with the Securities and Exchange Commission (SEC), including the annual report on Form 10-K for the year ended December 31, 2007 and other periodic reports filed with the SEC. Any forward-looking statements in this press release represent Sucampo Pharmaceuticals' views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Sucampo Pharmaceuticals anticipates that subsequent events and developments will cause its views to change. However, while Sucampo Pharmaceuticals may elect to update these forward-looking statements publicly at some point in the future, Sucampo Pharmaceuticals specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise.
